Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion |
| Therapy | Larotrectinib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | colorectal cancer | sensitive | Larotrectinib | Phase II | Actionable | In a Phase II trial (NAVIGATE), Vitrakvi (larotrectinib) treatment resulted in an overall response rate (ORR) of 28% (12/43, 3 complete and 9 partial responses) and stable disease in 44% (19/43) of gastrointestinal cancer patients harboring NTRK fusions, ORR was 44% (11/25) in colorectal cancer patients and 40% (6/15) in those with microsatellite instability-high colorectal cancer (PMID: 40068370; NCT02576431). | 40068370 |
| NTRK1 fusion | colorectal cancer | sensitive | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic colorectal cancer harboring an NTRK fusion (PMID: 36307056; ESMO.org). | 36307056 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| (36307056) | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |
| (40068370) | Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. | Full reference... |